Efficacy and Safety of Albumin-bound Paclitaxel as Second-line Treatment in Advanced Triple Negative Breast Cancer
ZHAN Peng
GUO Fang
GE Ya-nan
ZHANG Guan-zhong
XIE Xiao-dong
Abstract：Objective To evaluate the efficacy and safety of Albumin-bound paclitaxel as second-line treatment in ad-vanced triple negative breast cancer ( TNBC) . Methods Clinical data of 21 patients with advanced TNBC under going Albumin-bound paclitaxel as second-line chemotherapy during February 2011 and October 2014 were analyzed. Albumin-bound paclitaxel was given via intravenous drip at 125 mg/m2(on the first day and eighth day), and a cycle was 21 days. The adverse reactions were e-valuated every cycle until progression of disease or intolerable adverse reaction occurred. The short-term response was evaluated ev-ery two cycles. The patients were followed-up, and the survival condition was analyzed. Results 21 patients completed 109 cycles of chemotherapy, with an average of 5. 4 cycles. All the patients were evaluable for treatment response. The median follow-up time was 6. 9 months. There were 3 cases of partial response;14 cases of stable disease and 4 of progressive disease. The rate of RR was 14. 3%, DCR was 66. 7%. The median PFS was 4. 7 months, and the median OS was 6. 9 months. There was no treatment-related death. The major side effects were myelosuppression. There were 7 cases of neutropenia (33. 3%), 3 cases of thrombocytopenia (14. 3%), 2 cases of anemia (9. 5%), 1 case of lack of granulocyte fever (4. 8%). Conclusion Albumin-bound paclitaxel as second-line chemotherapy treatment in advanced TNBC is effective with good tolerance for adverse reactions.
Keywords：Breast neoplasmAlbumin-bound paclitaxelDrug therapycombination
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 55-57 )